INZY Description — Inozyme Pharma Inc
Inozyme Pharma is a rare disease biopharmaceutical company developing therapeutics for the treatment of diseases of abnormal mineralization impacting the vasculature, soft tissue and skeleton. Co.'s product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in the mineralization pathway caused by ectonucleotide pyrophosphatase/phosphodiesterase 1 and adenosine triphosphate-Binding Cassette in the C6 Deficiencies. This pathway is central to the regulation of calcium deposition throughout the body and is further associated with neointimal proliferation, or the overgrowth of smooth muscle cells inside blood vessels.
|
|
Free INZY Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Strong Buy (3.83 out of 4) 73rd percentile
(ranked higher than approx. 73% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |
|